

AI acquisition
international
the sector of modern business - est. 2000

Research & Development awards 2022



intelli

 **BIGFOOT**
WEB A Peak Seven Company

About the Research & Development Awards 2022

No information contained on or in this website constitutes investment advice or an offer to invest or to provide management services and is subject to correction, completion and amendment without notice. Neither AI nor any of its associated entities are authorised to give financial advice of any nature nor are they regulated by the Financial Services Authority.

Prior to making any investment, AI recommends that any prospective investor should consult with its own investment, accounting, legal and tax advisers to evaluate independently the risks, consequences and suitability of that investment.

AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them.

The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions.

Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.

Acquisition International is proud to host the Research and Development Awards for 2022

We have seen greater importance for this sector over the past 18-24 months with the global pandemic constantly evolving. Due to the global pandemic, the significance of R&D in making a positive change to global markets has been emphasised. Utilising insights and information to determine how consumer needs and desires have changed, Research and Development helps to bring consumer expectations into a reality.



Sif Brookes - Senior Editor



Contents

- 4** *ETR: Best Medical Gas Engineering Solutions Provider - Central China*
- 6** *OTSL Germany: Most Advanced Automotive Simulator Company 2022*
- 8** *Selecta Biotech SE: Best MedTech Innovation of the Year 2022 - EU*
- 10** *Bigfoot Web: Best Cost-Efficient Web Design Company - Colorado*
- 12** *V.M.Z. Vermögensverwaltungsgesellschaft Dr.Markus C. Zschaber GmbH: Best Capital Market Research Company 2022*
- 14** *Angkasa-X Innovation: Most Innovative Satellite Research & Development Company - Malaysia*
- 16** *Hangzhou Energy and Environmental Engineering: Leading R&D Center for Biogas Engineering 2022*
- 18** *Royal Oak Health Ltd: Excellence Award in Food Manufacturing R&D 2022*
- 19** *MarkData (Pty) Ltd: Excellence Award for Human Behaviour Science R&D Services 2022*
- 20** *Dr Bonaros: Best Hair Transplant Clinic - Scotland*
- 21** *AsiaOne: Best International Media House & Research Company 2022- Asia*
- 22** *SICGEN Research and Development in Biotechnology Ltd: Best Biotechnology R&D Company - Portugal*
- 23** *Beyond the Narrative: Rising Stars in Market Research 2022 – APAC*
- 24** *Lusio Rehab: Assistive Technology Innovation of the Year 2022: LusioMATE*
- 25** *HTAG: Leading Champions of Care Improvement & Community Support 2022 – Australia & Healthcare Innovation Award 2022*
- 26** *isobiotec: Best Research Institute Product Engineers – Germany*

Editorial Team

Sif Brookes, Senior Editor
Sofi Bajor, Editor
Daniel Long, Writer

Gabriel Muers, Writer
Rebecca Scotland, Writer
Dontae Jones, Writer
Amelia Walker, Writer

Design Team

Daniela Levinte, Graphic Designer
Lauren Baldwin, Junior Graphic Designer



- 27 PsiVac:**
Best Oncolytic Viral Therapy Developers 2022
- 28 LatinNews:** Best Foreign News Provider 2022
- 29 Crystal Software Pty Ltd:** Best Crystallography Software Platform 2022: Crystal Studio
- 30 Smell Away Ltd:** Leader in Research and Development – North Wales
- 31 Res Media:** Best App Development & eCommerce Solutions - Italy
- 32 NIOX Group plc:** NIOX® - Leaders in FeNO Testing Technology Development 2022
- 33 Intellio:** Most Unique CRM Platform 2022
- 34 Orange River Wealth:** Best Boutique Investment Partnership - London
- 35 Rainbow Care Home Services:** Community Services Innovator of the Year 2022 - QLD
- 36 Define Normal Life Style Supports:** Leading Innovators in Ex-Con Support & Development 2022 – QLD & Excellence Award in Autism Research Fundraising 2022

Best Biotechnology R&D Company - Portugal

Antibodies are big business in North America, but Europe has surprisingly few options available to them. The team at SICGEN was founded with the intention of turning things around, producing high quality antibodies at competitive prices in the heart of Portugal. The team's success has pushed them into new territory, so we took a closer look at the firm to find out more.

Founded in 2009, SICGEN has gone from strength to strength over the last decade. Using the latest that technology has to offer, the team has established itself as a leading producer of polyclonal antibodies and antibody-related products and services. The demand for the team's products has seen them used in several Life Sciences research areas, expanding to include nearly 300 products.

The primary use of antibodies has been in research, with the SICGEN team providing polyclonal antibodies for leading national and international institutions, including universities, research institutes, pharmaceutical manufacturers and biotechnology distributors worldwide. The main markets are in North America, Europe and the Far East. From humble beginnings in Portugal, SICGEN has become world-renowned for its efforts.

The team's antibodies come from an unlikely source, namely goats. Turning to this natural source has allowed the team to increase the amount produced per animal keeping production quality up and costs down. The use of cutting-edge technologies throughout the process such as recombinant proteins produced in laboratory for immunisation and affinity purification has gone a long way to making this dream happen. Needless to say, the team's high quality products have been used in numerous research projects, and the resultant scientific papers produced mentioning the team have gone a long way to advertise the business.

This innovative streak has driven much of the team's work, with SICGEN using R&D to explore new ideas and gaps in the market. The competitiveness of the industry means there is always the need to develop new antibodies and improve the ones that already exist. For many businesses in this sector, stagnation sets in swiftly, and stifles the development of those companies which do not innovate enough. There is, however, plenty of space that can be operated within. Numerous gaps in the market still have yet to be filled, and it's those who are always looking forward that will fill them.

The antibody industry is one that has expanded significantly over the last decade, with SICGEN often at the forefront of that incredible wave of innovation. Many customers have found that working with smaller companies such as SICGEN means they can gain a more flexible source of antibodies and a more individualistic approach that meets their specific needs perfectly.



The future for the industry looks bright indeed, driven by new ideas and bold propositions. The biotech industry is likely to see numerous advances in in-vitro technologies, using non-animal-based approaches for antibody generation. These new ways of working will offer greater versatility and reproducibility over animal immunisation, as well as alleviating ethical concerns. The world is always moving forward, but the secret behind the success of SICGEN is that they are always moving forward too.

When SICGEN was first founded, it was in the wake of a major financial crisis that affected the whole world. Now, with difficult times ahead for all of us, the team stand as one of the most resilient in the industry, able to meet the unique needs of clients with ease. They will continue to develop, produce and market new antibody products, leading the way when it comes to providing solutions in niche areas. As a business that takes the time to understand what clients need, they are happy to have secured astonishingly high levels of success.

Company: SICGEN Research and Development in Biotechnology Ltd
 Name: Jose Ramalho
 Email: jramalho@sicgen.pt
 Web Address: www.sicgen.pt



AI

acquisition
international

the voice of modern business - est. 2010